Company / Cash & Equivalents
ORAMED PHARMACEUTICALS INC. Cash & Equivalents History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$45.9M
FY2025
5-year range
$9.1M / $45.9M
FY2021-FY2025
Trend
-
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Cash & Equivalents changed +407% YoY in FY2025, a notable deviation from the 7-year average annual change of +133%.
Based on SEC 10-K filings.
$46M in FY2025 with a 5-year CAGR of +69.0%.
Improved from $19M to $46M over the past 4 years.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- +69.0%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of +69.0%, indicating consistent growth.
- Lowest cash & equivalents in the period was in FY2016.
Company context
Key Data Points
- Altman Z-Score 0.91 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $45.9M | - |
| FY2024 | - | - |
| FY2023 | $9.1M | - |
| FY2022 | - | - |
| FY2021 | $19.3M | +479.6% |
| FY2020 | $3.3M | -33.4% |
| FY2019 | $5.0M | +27.9% |
| FY2018 | $3.9M | +21.6% |
| FY2017 | $3.2M | +82.3% |
| FY2016 | $1.8M | - |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026